Go to PegaPoll
PEGAPOLL · NEWS

CG Oncology bladder immunotherapy cretostimogene cut recurrence risk by 68% in phase 3 study

STAT News · 2026-11-16
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

CG Oncology reported Monday that its bladder cancer immunotherapy cretostimogene reduced the risk of tumor recurrence by 68% compared with current medical practice, results from a randomized Phase 3 trial that may change how physicians treat some patients with the disease. Cretostimogene, often called “creto,” is built from a common-cold virus engineered to target cells that express a mutation found in bladder tumors. Doctors infuse it through a catheter directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, and ruptures those cells.

The study enrolled 367 patients with intermediate-risk bladder cancer, a localized form typically removed with minimally invasive surgery and then watched every three months. Recurrence can mean repeat operations; over time, bladder function can decline and the cancer can keep growing. The trial compared cretostimogene with that standard of care rather than with a new rival drug. The source’s remaining clinical details sit behind a STAT+ paywall, so further endpoints, safety data, and subgroup results were not available in the published excerpt.

Continue in the app — vote & join in ➔
Source: STAT News · via ahirlevel.hu

Related news